After the initial focus on five areas to watch out for in the bispecific field at AACR22, we now turn our attention to a much broader and deeper look at the emerging landscape.

In this preview we highlight many of the new targets and molecules coming through company pipelines, some of which are likely to be licensing-in candidates for bigger companies seeking to replenish their pipelines.

It occurred to me this scenario is a bit like finding a hidden path you never knew existed, with rows of boats (or bispecifics in this case) lined up for inspection…

BSB subscribers can read our latest landscape review and critical commentary – you can either log-in or click to access.

This content is restricted to subscribers

Posted by